A Phase I/II Clinical Trial Of Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable (Stage III) Lung Cancers
- Histologically confirmed lung cancer, excluding small cell carcinoma
- Inoperable stage I (T1-2N0) and II (T1-2N1, T3N0) disease, or stage IIIA (T3N1
andT1-3N2M0) and IIIB (TxN3M0, T4NxM0) diseases according to the American Joint
Committee of Cancer criteria 1998
- The primary tumor must be radiographically measurable.
- Age > 18.
- Karnofsky performance status > 70.
- FEV1 sufficient for patients to tolerate radiation therapy which is at the discretion
of the radiation oncologist, usually > 800 ml
- Labs: WBC > 3000; platelet count > 100,000; serum creatinine < 1.5 mg/dl or
creatinine clearance >60 ml/min.
- Laboratory values must be obtained < 3 weeks prior to registration.
- A signed informed consent.
- Patients who failed prior chemotherapy are eligible. Patients with prior radiotherapy
to the chest region are eligible as long as the normal tissue tolerance is not
violated by repeat radiotherapy.
- Patients with medical contraindication to chemotherapy or radiotherapy.
- Patients with myocardial infarction within the preceding six months or symptomatic
heart disease, including uncontrolled or unstable angina, uncontrolled congestive
heart failure, and uncontrolled arrhythmia.
- Women who are pregnant.
- Patients with small cell carcinoma or mesothelioma